SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Bosch J)
 

Sökning: WFRF:(Bosch J) > (2010-2014) > Impact of Human Pap...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005793naa a2200793 4500
001oai:lup.lub.lu.se:4e5d23d7-9f68-41f9-8dbe-a8505c701bcb
003SwePub
008160404s2010 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:120122260
0247 a https://lup.lub.lu.se/record/15528142 URI
0247 a https://doi.org/10.1093/jnci/djp5342 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1201222602 URI
040 a (SwePub)lud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Muñoz, Nubia4 aut
2451 0a Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women.
264 c 2010-03-03
264 1b Oxford University Press (OUP),c 2010
520 a Background The impact of the prophylactic vaccine against human papillomavirus (HPV) types 6, 11, 16, and 18 (HPV6/11/16/18) on all HPV-associated genital disease was investigated in a population that approximates sexually naive women in that they were "negative to 14 HPV types" and in a mixed population of HPV-exposed and -unexposed women (intention-to-treat group). Methods This analysis studied 17 622 women aged 15-26 years who were enrolled in one of two randomized, placebo-controlled, efficacy trials for the HPV6/11/16/18 vaccine (first patient on December 28, 2001, and studies completed July 31, 2007). Vaccine or placebo was given at day 1, month 2, and month 6. All women underwent cervicovaginal sampling and Papanicolaou (Pap) testing at day 1 and every 6-12 months thereafter. Outcomes were any cervical intraepithelial neoplasia; any external anogenital and vaginal lesions; Pap test abnormalities; and procedures such as colposcopy and definitive therapy. Absolute rates are expressed as women with endpoint per 100 person-years at risk. Results The average follow-up was 3.6 years (maximum of 4.9 years). In the population that was negative to 14 HPV types, vaccination was up to 100% effective in reducing the risk of HPV16/18-related high-grade cervical, vulvar, and vaginal lesions and of HPV6/11-related genital warts. In the intention-to-treat group, vaccination also statistically significantly reduced the risk of any high-grade cervical lesions (19.0% reduction; rate vaccine = 1.43, rate placebo = 1.76, difference = 0.33, 95% confidence interval [CI] = 0.13 to 0.54), vulvar and vaginal lesions (50.7% reduction; rate vaccine = 0.10, rate placebo = 0.20, difference = 0.10, 95% CI = 0.04 to 0.16), genital warts (62.0% reduction; rate vaccine = 0.44, rate placebo = 1.17, difference = 0.72, 95% CI = 0.58 to 0.87), Pap abnormalities (11.3% reduction; rate vaccine = 10.36, rate placebo = 11.68, difference = 1.32, 95% CI = 0.74 to 1.90), and cervical definitive therapy (23.0% reduction; rate vaccine = 1.97, rate placebo = 2.56, difference = 0.59, 95% CI = 0.35 to 0.83), irrespective of causal HPV type. Conclusions High-coverage HPV vaccination programs among adolescents and young women may result in a rapid reduction of genital warts, cervical cytological abnormalities, and diagnostic and therapeutic procedures. In the longer term, substantial reductions in the rates of cervical, vulvar, and vaginal cancers may follow.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Kjaer, Susanne K4 aut
7001 a Sigurdsson, Kristján4 aut
7001 a Iversen, Ole-Erik4 aut
7001 a Hernandez-Avila, Mauricio4 aut
7001 a Wheeler, Cosette M4 aut
7001 a Perez, Gonzalo4 aut
7001 a Brown, Darron R4 aut
7001 a Koutsky, Laura A4 aut
7001 a Tay, Eng Hseon4 aut
7001 a Garcia, Patricía J4 aut
7001 a Ault, Kevin A4 aut
7001 a Garland, Suzanne M4 aut
7001 a Leodolter, Sepp4 aut
7001 a Olsson, Sven-Eriku Karolinska Institutet4 aut
7001 a Tang, Grace W K4 aut
7001 a Ferris, Daron G4 aut
7001 a Paavonen, Jorma4 aut
7001 a Steben, Marc4 aut
7001 a Bosch, F Xavier4 aut
7001 a Dillner, Joakimu Karolinska Institutet,Lund University,Lunds universitet,Klinisk mikrobiologi, Malmö,Forskargrupper vid Lunds universitet,Clinical Microbiology, Malmö,Lund University Research Groups4 aut0 (Swepub:lu)mikr-jdi
7001 a Huh, Warner K4 aut
7001 a Joura, Elmar A4 aut
7001 a Kurman, Robert J4 aut
7001 a Majewski, Slawomir4 aut
7001 a Myers, Evan R4 aut
7001 a Villa, Luisa L4 aut
7001 a Taddeo, Frank J4 aut
7001 a Roberts, Christine4 aut
7001 a Tadesse, Amha4 aut
7001 a Bryan, Janine T4 aut
7001 a Lupinacci, Lisa C4 aut
7001 a Giacoletti, Katherine E D4 aut
7001 a Sings, Heather L4 aut
7001 a James, Margaret K4 aut
7001 a Hesley, Teresa M4 aut
7001 a Barr, Eliav4 aut
7001 a Haupt, Richard M4 aut
7102 a Karolinska Institutetb Klinisk mikrobiologi, Malmö4 org
7730 t Journal of the National Cancer Instituted : Oxford University Press (OUP)g 102, s. 325-339q 102<325-339x 1460-2105x 0027-8874
8564 u http://www.ncbi.nlm.nih.gov/pubmed/20139221?dopt=Abstracty FULLTEXT
8564 u http://dx.doi.org/10.1093/jnci/djp534y FULLTEXT
8564 u https://academic.oup.com/jnci/article-pdf/102/5/325/17310863/djp534.pdf
8564 8u https://lup.lub.lu.se/record/1552814
8564 8u https://doi.org/10.1093/jnci/djp534
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:120122260

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy